1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Drugs In Development, 2022, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 8, 15, 5 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 4, 3 and 3 molecules, respectively.
Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Cervical Intraepithelial Neoplasia (CIN) - Overview
- Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development
- Cervical Intraepithelial Neoplasia (CIN) - Drug Profiles
- Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects
- Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products
- Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones
- Featured News & Press Releases
- Mar 08, 2022: Nykode Therapeutics to present at 2022 American Association for Cancer Research (AACR) Annual Meeting
- Dec 14, 2021: INOVIO highlights key updates on phase 3 program for VGX-3100, its DNA-based immunotherapy for the treatment of cervical HSIL caused by HPV-16 and/or HPV-18
- Apr 21, 2021: Antiva Biosciences appoints Clifford Samuel to Board of Directors
- Mar 26, 2021: The VGX-3100 project of Dongfanglue passed the approval of the Genetics Office, and officially launched the domestic phase III clinical trial
- Feb 20, 2020: Novan receives phase 2 NIH federal grant of approximately $1.0 million
- Dec 03, 2019: PDS Biotechnology to present at the 12th Annual LD Micro Main Event
- Nov 25, 2019: PDS Biotechnology to present at the World Vaccine & Immunotherapy Congress West Coast 2019
- Nov 06, 2019: PDS Biotechnology accepted for oral presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting
- Oct 01, 2019: PDS Biotechnology prioritizes development of PDS0101 in advanced cancers following promising phase 1 clinical outcome data
- Sep 19, 2019: PDS Biotechnology reports clinical data for its novel immunotherapy PDS0101 in follow up to phase 1 human trial
- Jun 26, 2019: Inovio completes enrollment of VGX-3100 phase 3 trial (reveal 1) for the treatment of HPV-related cervical pre-cancer
- Jun 05, 2019: Peer-reviewed publication confirms the potential of Transgene' TG4001
- May 06, 2019: Inovio receives European Medicines Agency Certification for quality and non-clinical data for its Phase 3 product, VGX-3100
- Apr 17, 2019: Inovio's phase 3 HPV immunotherapy selected as "Best Therapeutic Vaccine" at World Vaccine Congress
- Apr 03, 2019: Therapy completely clears HPV in one-third of cervical precancers
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, 2022
- Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, 2022
- Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Antiva Biosciences Inc
- Asieris Pharmaceuticals Co Ltd
- Beijing Kangle Guardian Biotechnology Co Ltd
- Beijing Kangleweishi Biotechnology Co Ltd
- Bioleaders Corp
- Blue Sky Immunotherapies GmbH
- CEL-SCI Corp
- Chengdu Institute of Biological Products Co Ltd
- Douglas Pharmaceuticals Ltd
- Frantz Viral Therapeutics LLC
- Genexine Inc
- GenoLac BL Corp
- Hefei Ruichengsheng Biotechnology Co Ltd
- Inovio Pharmaceuticals Inc
- KinoPharma Inc
- Merck & Co Inc
- Novan Inc
- Nykode Therapeutics ASA
- Papivax LLC
- PDS Biotechnology Corp
- Shanghai Bovax Biotechnology Co Ltd
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- Transgene SA
- Vaccitech Plc
- Vaxart Inc
- ViciniVax BV
